Altogether these results support the premise that PEDF treatment reduces pro-metastatic phenotypes of TNBC cells under pre-menopausal oestrogen conditions and ER+/HER2- BC cells under post-menopausal oestrogen conditions, which may be relevant for the development of BC bone metastases. This evidence concerns the gene ERBB2 and breast cancer.